This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Stock Picks for Week of January 15, 2024
by Panel Of Zacks Experts
An Interesting Mid Cap Stock and a Small-Cap Provider of Cancer Genetics Diagnostics for Your Consideration.
NeoGenomics and Marvell Technology have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
NeoGenomics and Marvell Technology are part of the Zacks Bull and Bear of the Day article.
Bull of the Day: NeoGenomics (NEO)
by Kevin Cook
Small-cap leader in oncology diagnostics is on sale after patent litigation takes a bite
Best Momentum Stocks to Buy for January 9th
by Zacks Equity Research
NEO, WIX and LNW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 9, 2024.
New Strong Buy Stocks for January 9th
by Zacks Equity Research
NEO, WIX, LNW, TM and RBB have been added to the Zacks Rank #1 (Strong Buy) List on January 9, 2024.
Wall Street Analysts See a 28.17% Upside in NeoGenomics (NEO): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 28.2% in NeoGenomics (NEO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Compared to Estimates, NeoGenomics (NEO) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for NeoGenomics (NEO) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics (NEO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
NeoGenomics (NEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Think NeoGenomics (NEO) Could Surge 35.08%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 35.1% upside potential for NeoGenomics (NEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Bull of the Day: NeoGenomics (NEO)
by Kevin Cook
Diagnostic lab companies were hit by new FDA rules but this cancer fighter rebounds under 3X sales
NeoGenomics and SolarEdge Technologies have been highlighted as Zacks Bull and Bear of the Day
by Santanu Roy
NeoGenomics and SolarEdge Technologies are part of the Zacks Bull and Bear of the Day article.
NeoGenomics (NEO) Soars 8.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
NeoGenomics (NEO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
NeoGenomics (NEO) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
NeoGenomics (NEO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NeoGenomics (NEO) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for NeoGenomics (NEO) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks.com featured highlights include First Watch Restaurant, NeoGenomics and Universal Stainless & Alloy Products
by Zacks Equity Research
First Watch Restaurant, NeoGenomics and Universal Stainless & Alloy Products are part of the Zacks Screen of the Week article.
3 Best Breakout Stocks to Invest in for Superlative Returns
by Tirthankar Chakraborty
First Watch Restaurant Group (FWRG), NeoGenomics (NEO), and Universal Stainless & Alloy Products (USAP) have been selected as the breakout stocks for today.
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 35.71% and 8.64%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights Portillo's, NeoGenomics and Wingstop
by Zacks Equity Research
Portillo's, NeoGenomics and Wingstop have been highlighted in this Screen of The Week article.
3 Top Stocks Likely to Exceed Estimates This Earnings Season
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap Portillo's Inc. (PTLO), NeoGenomics (NEO) and Wingstop (WING).
Zacks.com featured highlights include Lamb Weston, NeoGenomics, Surrozen, KE Holdings and Insperity
by Zacks Equity Research
Lamb Weston, NeoGenomics, Surrozen, KE Holdings and Insperity are part of the Zacks Screen of the Week article.
5 Top Stocks Likely to Come Up With Earnings Beat
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom line in their next releases. Tap Lamb Weston (LW), NeoGenomics (NEO), Surrozen (SRZN), KE Hodlings (BEKE) and Insperity (NSP).
Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 15.38% and 10.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 60% and 6.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Predict a 41% Upside in NeoGenomics (NEO): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for NeoGenomics (NEO) points to a 40.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.